The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
about
Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaksTrial watch - inhibiting PARP enzymes for anticancer therapyPARP inhibitors in the management of breast cancer: current data and future prospectsNew molecular targets in mantle cell lymphomaTargeting ATM-deficient CLL through interference with DNA repair pathwaysPARPs and the DNA damage responseNovel agents in mantle cell lymphomaSapacitabine for cancerNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCIViC databaseLow ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.Integrative clinical genomics of advanced prostate cancer.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling.Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neuronsDoxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent mannerAcetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM geneATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Development of synthetic lethality anticancer therapeutics.Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function.JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.Molecular targeted approaches in mantle cell lymphoma.Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Rare variants in the ATM gene and risk of breast cancerA new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity.Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virusAssessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita miceEnhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Molecular pathogenesis of mantle cell lymphoma.Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
P2860
Q24337442-7474309F-4850-428F-A846-583F1F380EC8Q26745673-E9AFFEEB-57ED-48D3-A83D-3831FFC4F41EQ26798352-A1F4C668-7752-4CC0-97F7-5E527ACA17EDQ26821766-1FD542C0-7421-4A10-8927-F4E4B0557CFEQ26822592-50C7E225-1A1B-466D-AA75-7A5AB6AF0761Q26859010-64267CED-D06D-4D72-A979-DC92DC50F213Q27011763-43756E1D-A72F-4797-BD8E-E2DB97D7409BQ27024675-286FF003-72E8-4A49-A822-B8AF61A33CF8Q27304386-4B6DA771-D0E0-4430-A34C-379171603989Q27612411-9F3F6514-CB89-427B-AAEF-65E76BBB1CD3Q27853007-BB6C6ED7-8F40-45FC-A0DC-DBF2E8F63088Q27853170-92CE531A-DF48-46E9-9D33-A96E8B1A344DQ33409459-9F976384-E51A-4EF4-BBEE-E8C5BAA7C3F2Q33612686-1730A8ED-3C33-48F7-94F0-0B5FA18A265FQ33865342-30CA4A0A-E910-4BCA-990E-E72F763EF466Q33952953-0734A629-123E-4FF2-A0CA-3989A8BF1D2DQ34004402-1CDA1638-4363-487D-8042-3318CD7DF27CQ34224906-A29F35BD-9D34-413E-B4EC-D1AD75C5C79AQ34249365-B1466E07-8BCD-4AC7-B591-692D7E601606Q34380368-A8DFB4BA-8174-455A-ACA3-B59AA5423ACBQ34532980-359887AC-9735-48C3-9EA6-72625AA5D5BBQ34602683-E1F5DDFF-D688-43D2-BF8A-DF30637A9C99Q34851871-C722CAFF-1C90-4A06-B686-48A7AC09E260Q34993640-53515C11-9AA4-4768-B901-EE390EBB3D55Q35051154-B7E992F3-7C06-4B21-B62D-96B19C259FACQ35051517-9C73D907-4EB6-4E97-8183-87CD0521A1F2Q35127368-0CB558DD-5C21-4060-83DE-6884F8F7092CQ35220403-DD7B873B-8C89-4CBD-B484-873E7C93A8D9Q35588352-A3B202C0-D2EB-489E-B132-ABFA883A1F71Q35608690-827B8D18-BA13-46A4-9B8D-8E650C11CB09Q35681896-D10CD67F-2701-4DF2-9D31-F8659BFB2AD1Q35832062-898694CE-E61C-4C88-ADC3-11A4A1A6E87FQ35879098-D396EB84-A6AC-4E99-A90E-7DD93D7A9649Q35922047-BF452F1D-5658-4464-AE57-105FDF3DF72BQ36022313-B8C7F1C7-BD97-4F55-B468-32599E55F8A6Q36032110-80CFEECD-9497-422E-A19B-D3E83DA1F07FQ36238650-C9D59D51-C21E-44B6-8559-FCE1FC6D112BQ36290246-F8765DFF-837F-4B1D-A7FB-37697D651A90Q36294441-01F0B0F8-78C5-4280-B66A-F5E2ABDEDC88Q36392466-8374C846-D7D5-4811-AF0D-47FD45CA5BEC
P2860
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@ast
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@en
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@nl
type
label
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@ast
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@en
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@nl
prefLabel
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@ast
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@en
The PARP inhibitor olaparib in ...... or cells in vitro and in vivo.
@nl
P2093
P3181
P1433
P1476
The PARP inhibitor olaparib in ...... mor cells in vitro and in vivo
@en
P2093
A Malcolm R Taylor
Anna Skowronska
Ceri E Oldreive
David G Oscier
Graeme Smith
Judy E Powell
Pamela Kearns
Paul A H Moss
Victoria J Weston
P304
P3181
P356
10.1182/BLOOD-2010-01-265769
P407
P577
2010-08-25T00:00:00Z